Risk and benefit of antibody induction therapy in combination with tacrolimus immunosuppression after liver transplantation.

[1]  U. Neumann,et al.  A prospective randomized trial comparing interleukin-2 receptor antibody versus antithymocyte globulin as part of a quadruple immunosuppressive induction therapy following orthotopic liver transplantation. , 1997, Transplantation.

[2]  S. Hammer,et al.  Major infectious complications after orthotopic liver transplantation and comparison of outcomes in patients receiving cyclosporine or FK506 as primary immunosuppression. , 1995, Transplantation.

[3]  Charles M. Miller,et al.  FK506 (tacrolimus) compared with cyclosporine for primary immunosuppression after pediatric liver transplantation: Results from the U.S. multicenter trial , 1995 .

[4]  W. Bechstein,et al.  Comparison of FK506- and cyclosporine-based immunosuppression in primary orthotopic liver transplantation. A single center experience. , 1995, Transplantation.

[5]  T. Starzl,et al.  A randomized trial of primary liver transplantation under immunosuppression with FK 506 vs cyclosporine. , 1991, Transplantation proceedings.

[6]  C. Gross,et al.  Chronic rejection after liver transplantation: A study of clinical, histopathological and immunological features , 1991, Hepatology.

[7]  H. Nazer,et al.  Lymphoproliferative disorder in a liver transplant patient on FK 506 , 1991, The Lancet.

[8]  M. Koulmanda,et al.  Cyclophosphamide promotes rejection of MHC-matched fetal pancreas allografts in mice. , 1989, Transplantation proceedings.

[9]  J. Neuberger.  Liver allograft rejection--current concepts on diagnosis and treatment. , 1995, Journal of hepatology.

[10]  H. Kreis.  Adverse events associated with OKT3 immunosuppression in the prevention or treatment of allograft rejection , 1993 .

[11]  M. Barr,et al.  Incidence of malignancies in renal and cardiac transplant recipients in relation to treatment with biologic agents , 1992 .